Marilyn Bui, MD, PhD, explores the pathogenesis and diagnosis of desmoid tumors, emphasizing the significance of a multidisciplinary diagnostic approach.
Chandrajit Raut, MD, provides an overview of the landscape surrounding desmoid tumors, highlighting associated epidemiology and common characteristics.
SpringWorks Therapeutics drug Ogsiveo is now FDA-approved for treating desmoid tumors, a type of tumor affecting connective tissue. The regulatory decision makes the pill the first therapy approved specifically for treating this rare disorder.